Evaluating Alcon (SWX:ALC) After Recent Share Price Weakness And Perceived Valuation Gap

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Recent share performance and business snapshot

Alcon (SWX:ALC) has drawn attention after a period where the stock is down about 10% over the past month and about 17% over the past 3 months, while the company’s eye care business generated CHF 10,634.0 million in revenue and net income of CHF 819.0 million.

See our latest analysis for Alcon.

Looking beyond the recent pullback, Alcon’s share price return is down over the year and over multi year periods, while the latest short term recovery hints that recent momentum has started to stabilise after heavier earlier declines in total shareholder returns.

If you are weighing opportunities in eye care and health focused technology, it can also be useful to see how other healthcare focused AI stocks are trading right now through 128 healthcare AI stocks

So with the share price under pressure, solid revenue of CHF 10,634.0 million and net income of CHF 819.0 million, and a reported discount to some valuation estimates, is this a potential entry point or is the market already pricing in future growth?

Most Popular Narrative: 33% Undervalued

Alcon’s most followed narrative points to a fair value of CHF 79.02 per share compared with the last close of CHF 53.28. This frames a sizeable valuation gap built on detailed growth and margin assumptions.

Accelerated new product launches, including Unity VCS (next‑gen surgical platform), PanOptix Pro (premium IOL), Tryptyr (first‑in‑class dry eye Rx), Precision7 (novel contact lens), and recent pipeline‑accretive M&A (STAAR, LumiThera, Voyager), provide significant near

and medium‑term opportunities for share gain, mix improvement, and new market entry, underpinning upside to both revenue and net margins as these innovations scale.

Read the complete narrative.

Curious how that product and acquisition pipeline translates into the fair value estimate? The narrative leans on specific revenue trajectories, margin uplift and a tighter share count. The mix of these levers, and how they stack across several years, is what really drives the gap to today’s price.

Result: Fair Value of CHF79.02 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on Alcon absorbing competitive pressure in intraocular lenses and successfully integrating recent acquisitions without margin drag or prolonged regulatory delays.

Find out about the key risks to this Alcon narrative.

Story Continues

Another Angle on Value: Earnings Multiple Tells a Different Story

While the narrative and DCF style fair value of CHF 79.02 suggest Alcon is 33% undervalued, the market is pricing the stock at a P/E of 40.4x, compared with 25.2x for peers and a fair ratio of 34.9x. That points to a richer earnings multiple and a possible valuation risk. Which signal would you lean on?

See what the numbers say about this price — find out in our valuation breakdown.SWX:ALC P/E Ratio as at May 2026

Next Steps

Seen enough to sense both optimism and caution in this story? Act while the facts are fresh by reviewing the full breakdown of 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop here, you risk missing other compelling setups that could fit your style. Take a moment to scan a few focused stock ideas first.

Target quality at a discount by reviewing 211 high quality undervalued stocks that pair solid fundamentals with prices below many valuation estimates. Build a steadier income stream by scanning 479 dividend fortresses that combine yield potential with an emphasis on resilience. Prioritise capital preservation by checking 311 resilient stocks with low risk scores chosen for comparatively lower risk scores without ignoring return potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ALC.SW.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments